1[1]Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet ,2002,359:1761 - 1767.
2[2]Li Ninghua, OU pinzhong, ZHU Hanmin,et al. Prevalence rate of osteoporosis in the mid - aged and elderly in selected parts of China.Chin Med J,2002,115:773 -775.
3[3]Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab ,2001,86:1212 - 1221.
4[4]lwamoto J, Takeda T, lchimura S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporsis. J Orthop Sci,2000,5:546 - 551.
5[5]Michael Bolognese. Effective pharmacotherapeutic interventions for the prevention of hip fractures. The Endocrinologist,2002,12:29 -37.
6[6]Khastgir G, Studd J, Holland N, et al. Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab,2001,86:289 - 295.
7[7]Evans G. The effects of raloxifene on tibia, histomorphometry in overiectomized rats. Endocrinology, 1994,134:2283 - 2284.
8[8]Sato M. Bryant HU, lversen P, et al. Advantages of raloxifene over alendronate or estrogen on non - reproductive and reproductvie tissues in the long - trem dosing of ovariectomized rats. J Pharmacol Exp Ther, 1996,279:298 - 302.
9[9]Taranta A, Brama, M, Teti A, et al. The selecive estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone,2002,30:368 - 376.
10[10]Yang NN, Venogopalann M. Identification of an estrogen response element activated by metabolites of 17 β-estradiol and raloxifene.Science, 1996,273 (5279): 1222 - 1225.
二级参考文献13
1Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, 1998, 279:1445-1451.
2Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA ,2002, 287:847-857.
3Compston JE. Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects. Reprod Med Rev, 1994, 3:209-224.
4Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA, 1997, 277:1140-1147.
5Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol,1995,85:304-313.
6Writing Group for the Women′s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women′s Health Initiative Randomized Controlled Trial. JAMA,2002, 288:321-333.
7Bryant HU. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulator. Rev Endocr Metab Disord,2001,2:129-138.
8Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med, 1997, 337:1641-1647.
9Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigator
10Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res ,1998, 13:1747-1754.
